A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT00447993
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
67
Enrollment
INDUSTRY
Sponsor class
Conditions
Retinitis Pigmentosa
Interventions
COMBINATION_PRODUCT:
Low Dose NT-501
COMBINATION_PRODUCT:
High Dose NT-501
Sponsor
Neurotech Pharmaceuticals